Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Cellid Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02866006
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 120
- Registration Number
- NCT02866370
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧Great Western Hospital, Swindon, United Kingdom
🇬🇧The Christie Hospital, Manchester, United Kingdom
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
High-Risk Neuroblastoma Chemotherapy Without G-CSF
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT02786719
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 164
- Registration Number
- NCT02738346
- Locations
- 🇫🇷
Angers University Hospital, Angers, France
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-01-10
- Target Recruit Count
- 3
- Registration Number
- NCT02684071
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02649673
- Locations
- 🇺🇸
Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
🇺🇸Oklahoma University Health Science Center/Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT02631876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center, Augusta, Georgia, United States
🇺🇸UCLA Women's Health Clinical Research Unit - OBGYN, Los Angeles, California, United States
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 294
- Registration Number
- NCT02584478
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Shenyang, China
🇨🇳Obstetrics&Gynecology Hospital of Fudan University, Shanghai, Yangpu District, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 613
- Registration Number
- NCT02566993
- Locations
- 🇩🇪
Center for Pneumology and Thoracic Surgery, Gerlingen, Germany
🇧🇬University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski", Sofia, Sofia, Bulgaria
🇩🇪Vivantes Klinikum am Urban, Hämatologie und Onkologie, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.